TherapeuticsMD Announces Appointment of Mark Glickman as Chief Commercial Officer
BOCA RATON, Florida, October 15, 2021– (BUSINESS WIRE) – TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative company and leader in women’s health, today announced the appointment of Mark Glickman as Chief Commercial Officer of the Company.
Mr. Glickman previously served as Chief Commercial Officer of Esperion and Aralez Pharmaceuticals, and Executive Vice President, Sales and Marketing, of Auxilium Pharmaceuticals, among other global pharmaceutical roles. Mr. Glickman holds an MBA in International Finance and Management from New York University and a BA from State University of New York College in Oswego.
Nasdaq Listing Rule 5635 (c) (4) Incentive Grant
As an important incentive to accept the appointment of Mr. Glickman, TherapeuticsMD granted Mr. Glickman an allotment of 660,000 restricted stock units (“RSUs”) and 260,000 performance share units. (“PSU”) corresponding to ordinary shares of the Company, outside of the Company’s 2019 Incentive Plan (the “2019 Plan”). 400,000 of the RSUs will vest at the end of three years, and 260,000 of the RSUs will vest in equal annual installments over three years beginning October 15, 2022, in each case subject to Mr. Glickman’s continued service with the Society. PSUs will vest based on certain income-related performance measures and when the Company reaches breakeven EBITDA, and are subject to Mr. Glickman’s continued service to the Company. The actual number of PSUs that will vest will be between zero and two times the base number of PSUs depending on the milestones achieved. The incentive grant was approved on October 15, 2021 by a majority of independent directors of the Company’s board of directors on the basis of the employment incentive exception to shareholder approval provided by NASDAQ. Stock Market Listing Rule 5635 (c) (4).
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative and leading healthcare company focused on the development and commercialization of new products exclusively for women. Our products are designed to respond to the unique changes and challenges women face through the various stages of their lives with a therapeutic focus on family planning, reproductive health and menopause management. The company is committed to advancing women’s health and raising awareness of their health issues. To learn more about TherapeuticsMD, please visit treatmentsmd.com or follow us on Twitter: @TherapeuticsMD and on Facebook: TherapeuticsMD.
This TherapeuticsMD, Inc. press release may contain forward-looking statements. Forward-looking statements may include, without limitation, statements relating to the objectives, plans and strategies of TherapeuticsMD as well as statements, other than historical facts, which relate to activities, events or developments that the company has intention, expects, projects, believes or anticipates will or could occur in the future. These statements are often characterized by words such as “believes”, “hopes”, “could”, “anticipates”, “should”, “intends”, “plans”, “hopes”, “expects”. “,” Estimates “,” “projects”, “positioned”, “strategy” and similar expressions and are based on assumptions and assessments made in light of experience and management’s perception of historical trends, current conditions, expected future developments and other factors deemed appropriate. The forward-looking statements contained in this press release are made as of the date of this press release, and the company assumes no obligation to update or revise any such statements, whether as a result of new information, future events or otherwise. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are beyond the control of the company. Important factors that could cause actual results, developments and business decisions to differ materially from forward-looking statements are described in the sections entitled “Risk Factors” in the documents filed by the Company with the Securities and Exchange Commission, including its most recent annual report on Form 10 -K and quarterly reports on Form 10-Q, as well as reports on Form 8-K, and include the following: effects of the COVID-19 pandemic ; the company’s ability to maintain or increase sales of its products; the company’s ability to develop and market IMVEXXY®, ANNOVERA® and BIJUVA® and to obtain the additional financing required for this purpose; whether the company will be able to meet the covenants and terms of its term loan facility; whether the company will be able to successfully divest or obtain an investment in its vitaCare business and how the proceeds that may be generated by such divestiture or investment will be used; the potential for unwanted side effects or other safety risks that could adversely affect the marketing of the Company’s current or future approved products or prevent the approval of the Company’s future drug candidates; whether the FDA will approve the lower dose of BIJUVA; the company’s ability to protect its intellectual property, including with respect to paragraph IV notification letters the company has received regarding IMVEXXY and BIJUVA; the length, cost and uncertain results of future clinical trials; the company’s dependence on third parties to conduct its manufacturing, research and development and clinical trials; the ability of the company’s licensees to market and distribute the company’s products; the ability of the company’s marketing subcontractors to market ANNOVERA; the availability of reimbursement by government authorities and health insurance companies for company products; the impact of product liability lawsuits; the influence of extensive and costly government regulation; the volatility of the company’s common stock price and the concentration of power in its shareholders.
See the source version on businesswire.com: https://www.businesswire.com/news/home/20211015005639/en/
Lisa M. Wilson
Site Communications, Inc.